4 Feb 2016 07:00
For immediate release 4 February 2016
Sphere Medical Holding plc
("Sphere Medical" or the "Company")
Notice of Preliminary Results
Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, will announce its preliminary results for the year ended 31 December 2015 on Thursday 25 February 2016.
Dr. Wolfgang Rencken, Chief Executive Officer and Richard Wright, Chief Financial Officer, will host a presentation for analysts and conference call at 10:30am on the day of the results at Consilium Strategic Communications' offices, 41 Lothbury, London, EC2R 7HG.
- Ends -
For further information, please contact:
Sphere Medical Holding plc | Tel: +44 (0)1223 875 222 | |
Dr Wolfgang Rencken, Chief Executive Officer | ||
Richard Wright, Chief Financial Officer | ||
Panmure Gordon | Tel: +44 (0) 20 7886 2500 | |
Freddy Crossley | ||
Duncan Monteith | ||
Tom Salvesen (Corporate Broking) | ||
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 | |
Mary-Jane Elliott | spheremedical@consilium-comms.com | |
Chris Gardner | ||
Ivar Milligan | ||
Hendrik Thys | ||
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.
Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.
The Company's strategy is focused on developing the Proxima (CE-marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already selling its Proxima 3 product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.
Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.
For further information, please visit www.spheremedical.com
Sphere Medical Holding (SPHR)